Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | Aminotransferase class III | 0.0044 | 0 | 0.5 |
Plasmodium falciparum | ornithine aminotransferase | 0.0044 | 0 | 0.5 |
Mycobacterium tuberculosis | Adenosylmethionine-8-amino-7-oxononanoate aminotransferase BioA | 0.0311 | 1 | 1 |
Mycobacterium tuberculosis | Probable aminotransferase | 0.0311 | 1 | 1 |
Echinococcus multilocularis | ornithine aminotransferase | 0.0044 | 0 | 0.5 |
Toxoplasma gondii | ornithine aminotransferase, mitochondrial precursor, putative | 0.0044 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0182 | 0.5179 | 1 |
Plasmodium vivax | ornithine aminotransferase, putative | 0.0044 | 0 | 0.5 |
Echinococcus granulosus | Aminotransferase class III | 0.0044 | 0 | 0.5 |
Chlamydia trachomatis | glutamate-1-semialdehyde-2,1-aminomutase | 0.0044 | 0 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.0598 | 0.1155 |
Onchocerca volvulus | 0.0182 | 0.5179 | 0.5 | |
Schistosoma mansoni | ornithine--oxo-acid transaminase | 0.0044 | 0 | 0.5 |
Mycobacterium ulcerans | adenosylmethionine-8-amino-7-oxononanoate aminotransferase | 0.0311 | 1 | 1 |
Echinococcus granulosus | ornithine aminotransferase | 0.0044 | 0 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0311 | 1 | 1 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.0598 | 0.1155 |
Wolbachia endosymbiont of Brugia malayi | acetylornithine transaminase protein | 0.0044 | 0 | 0.5 |
Brugia malayi | hypothetical protein | 0.0182 | 0.5179 | 1 |
Echinococcus multilocularis | ornithine aminotransferase | 0.0044 | 0 | 0.5 |
Trichomonas vaginalis | acetylornithine aminotransferase, putative | 0.0311 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 5.6234 uM | PubChem BioAssay. qHTS for Inhibitors of Vif-A3G Interactions: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 23.1093 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS Assay for Activators of ClpP. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1478 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent))] | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.